Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Labcorp Holdings Inc. (LH)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Labcorp Holdings Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 920148.
Total stock buying since 2015: $1,043,003.
Total stock sales since 2015: $222,322,901.
Total stock option exercises since 2015: $77,979,648.
Table 3. Detailed insider trading at Labcorp Holdings Inc. (LH) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2023-08-01 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 56 | .00 | 0 |
| 2023-06-29 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 212 | 240.00 | 50,880 |
| 2023-05-19 | Kirchgraber Paul R (CEO, Covance Drug Development) | Sale | 4,300 | 216.91 | 932,708 |
| 2023-05-19 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 4,300 | 182.51 | 784,793 |
| 2023-05-18 | Schroeder Mark S (EVP, Pres Diagnostics & COO) | Sale | 1,500 | 216.77 | 325,155 |
| 2023-05-18 | Schroeder Mark S (EVP, Pres Diagnostics & COO) | Option Ex | 1,500 | 130.60 | 195,900 |
| 2023-03-31 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 3,897 | 225.81 | 879,981 |
| 2023-03-02 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 1,340 | .00 | 0 |
| 2023-02-21 | Kirchgraber Paul R (CEO, Covance Drug Development) | Sale | 8,000 | 250.58 | 2,004,672 |
| 2023-02-21 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 3,000 | 182.51 | 547,530 |
| 2023-02-14 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 309 | 247.63 | 76,517 |
| 2023-02-11 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 180 | .00 | 0 |
| 2023-02-11 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 423 | .00 | 0 |
| 2023-02-11 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 483 | .00 | 0 |
| 2023-02-11 | Seltz Judith C (EVP, CHRO) | Option Ex | 236 | .00 | 0 |
| 2023-02-11 | Wengel Kathryn E (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 423 | .00 | 0 |
| 2023-02-11 | Davis Jeffrey A. (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Gilliland Dwight Gary (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Parham Richelle P (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 290 | .00 | 0 |
| 2023-02-11 | Kong Garheng (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 110 | .00 | 0 |
| 2023-02-11 | Schechter Adam H (President & CEO) | Option Ex | 2,656 | .00 | 0 |
| 2023-02-11 | Williams R Sanders (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Neupert Peter M (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Anderson Kerrii B (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 723 | .00 | 0 |
| 2023-02-11 | Belingard Jean-luc (Director) | Option Ex | 742 | .00 | 0 |
| 2023-02-11 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 290 | .00 | 0 |
| 2023-02-07 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 409 | 243.01 | 99,391 |
| 2023-02-07 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 219 | 243.01 | 53,219 |
| 2023-02-04 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 267 | .00 | 0 |
| 2023-02-04 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 560 | .00 | 0 |
| 2023-02-04 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 560 | .00 | 0 |
| 2023-02-04 | Seltz Judith C (EVP, CHRO) | Option Ex | 280 | .00 | 0 |
| 2023-02-04 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 560 | .00 | 0 |
| 2023-02-04 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 300 | .00 | 0 |
| 2023-02-04 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 150 | .00 | 0 |
| 2023-02-04 | Schechter Adam H (President & CEO) | Option Ex | 3,507 | .00 | 0 |
| 2023-02-04 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 970 | .00 | 0 |
| 2023-02-04 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 374 | .00 | 0 |
| 2023-02-03 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 324 | 253.90 | 82,263 |
| 2023-02-03 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 173 | 253.90 | 43,924 |
| 2023-02-02 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 220 | .00 | 0 |
| 2023-02-02 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 443 | .00 | 0 |
| 2023-02-02 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 443 | .00 | 0 |
| 2023-02-02 | Seltz Judith C (EVP, CHRO) | Option Ex | 220 | .00 | 0 |
| 2023-02-02 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 443 | .00 | 0 |
| 2023-02-02 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 237 | .00 | 0 |
| 2023-02-02 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 117 | .00 | 0 |
| 2023-02-02 | Schechter Adam H (President & CEO) | Option Ex | 2,773 | .00 | 0 |
| 2023-02-02 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 767 | .00 | 0 |
| 2023-02-02 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 297 | .00 | 0 |
| 2022-11-08 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 1,116 | 232.67 | 259,659 |
| 2022-09-26 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 25,000 | 210.62 | 5,265,625 |
| 2022-09-07 | Caveney Brian J (EVP, President of Diagnostics) | Buy | 44 | 231.20 | 10,172 |
| 2022-08-03 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Sale | 32,100 | 254.13 | 8,157,701 |
| 2022-08-03 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 32,100 | 148.56 | 4,768,776 |
| 2022-08-01 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Sale | 2,576 | 258.54 | 665,996 |
| 2022-08-01 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 817 | 73.30 | 59,882 |
| 2022-06-07 | Caveney Brian J (EVP, President of Diagnostics) | Buy | 42 | 242.19 | 10,172 |
| 2022-03-29 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 2,356 | 277.11 | 652,871 |
| 2022-03-29 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 2,449 | 277.11 | 678,642 |
| 2022-03-25 | Wengel Kathryn E (Director) | Option Ex | 603 | .00 | 0 |
| 2022-03-25 | Williams R Sanders (Director) | Sale | 572 | 272.98 | 156,144 |
| 2022-03-10 | Summy Amy B. (EVP, Chief Marketing Officer) | Sale | 249 | 262.21 | 65,290 |
| 2022-02-16 | Neupert Peter M (Director) | Buy | 3,500 | 263.80 | 923,300 |
| 2022-02-15 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 207 | 273.98 | 56,713 |
| 2022-02-15 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 207 | 273.98 | 56,713 |
| 2022-02-12 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 284 | .00 | 0 |
| 2022-02-12 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 317 | .00 | 0 |
| 2022-02-12 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 2,638 | .00 | 0 |
| 2022-02-12 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 284 | .00 | 0 |
| 2022-02-12 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 867 | .00 | 0 |
| 2022-02-12 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 940 | .00 | 0 |
| 2022-02-12 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 2,708 | .00 | 0 |
| 2022-02-07 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 204 | 277.38 | 56,585 |
| 2022-02-07 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 218 | 277.38 | 60,468 |
| 2022-02-04 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 267 | .00 | 0 |
| 2022-02-04 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 560 | .00 | 0 |
| 2022-02-04 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 560 | .00 | 0 |
| 2022-02-04 | Seltz Judith C (EVP, CHRO) | Option Ex | 280 | .00 | 0 |
| 2022-02-04 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 560 | .00 | 0 |
| 2022-02-04 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 300 | .00 | 0 |
| 2022-02-04 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 150 | .00 | 0 |
| 2022-02-04 | Schechter Adam H (President & CEO) | Option Ex | 3,507 | .00 | 0 |
| 2022-02-04 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 970 | .00 | 0 |
| 2022-02-04 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 373 | .00 | 0 |
| 2022-02-03 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 161 | 271.81 | 43,761 |
| 2022-02-03 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 172 | 271.81 | 46,751 |
| 2022-02-02 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 220 | .00 | 0 |
| 2022-02-02 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 443 | .00 | 0 |
| 2022-02-02 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 443 | .00 | 0 |
| 2022-02-02 | Seltz Judith C (EVP, CHRO) | Option Ex | 220 | .00 | 0 |
| 2022-02-02 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 443 | .00 | 0 |
| 2022-02-02 | Davis Jeffrey A. (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Gilliland Dwight Gary (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Parham Richelle P (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 236 | .00 | 0 |
| 2022-02-02 | Kong Garheng (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 116 | .00 | 0 |
| 2022-02-02 | Schechter Adam H (President & CEO) | Option Ex | 2,773 | .00 | 0 |
| 2022-02-02 | Williams R Sanders (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Neupert Peter M (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Anderson Kerrii B (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 766 | .00 | 0 |
| 2022-02-02 | Belingard Jean-luc (Director) | Option Ex | 771 | .00 | 0 |
| 2022-02-02 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 296 | .00 | 0 |
| 2021-12-15 | Gilliland Dwight Gary (Director) | Sale | 500 | 302.27 | 151,137 |
| 2021-11-05 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 2,010 | .00 | 0 |
| 2021-11-05 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 2,010 | .00 | 0 |
| 2021-11-01 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 2,007 | .00 | 0 |
| 2021-11-01 | Schechter Adam H (President & CEO) | Option Ex | 2,007 | .00 | 0 |
| 2021-11-01 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 9,024 | .00 | 0 |
| 2021-09-15 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 4,500 | 296.78 | 1,335,509 |
| 2021-09-15 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 4,500 | 84.86 | 381,870 |
| 2021-08-01 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 50 | .00 | 0 |
| 2021-06-07 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 4,500 | 266.56 | 1,199,520 |
| 2021-06-07 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 4,500 | 84.86 | 381,870 |
| 2021-05-06 | Kirchgraber Paul R (CEO, Covance Drug Development) | Sale | 2,500 | 276.55 | 691,375 |
| 2021-05-03 | Belingard Jean-luc (Director) | Sale | 2,600 | 269.15 | 699,802 |
| 2021-05-03 | Belingard Jean-luc (Director) | Option Ex | 2,600 | 98.49 | 256,074 |
| 2021-04-03 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 1,010 | .00 | 0 |
| 2021-03-30 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 667 | 251.88 | 168,003 |
| 2021-03-30 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 812 | 251.88 | 204,526 |
| 2021-02-18 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Sale | 2,317 | 241.51 | 559,590 |
| 2021-02-18 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 2,166 | 164.55 | 356,415 |
| 2021-02-16 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 188 | 237.06 | 44,567 |
| 2021-02-16 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 208 | 236.33 | 49,157 |
| 2021-02-12 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 517 | .00 | 0 |
| 2021-02-12 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 581 | .00 | 0 |
| 2021-02-12 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 2,870 | .00 | 0 |
| 2021-02-12 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 573 | .00 | 0 |
| 2021-02-12 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 867 | .00 | 0 |
| 2021-02-12 | Eisenberg Glenn A (Chief Financial Officer, EVP) | Option Ex | 1,720 | .00 | 0 |
| 2021-02-12 | Berberian Lance (EVP, CIO & CTO) | Option Ex | 2,940 | .00 | 0 |
| 2021-02-05 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Sale | 203 | 225.85 | 45,847 |
| 2021-02-05 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Sale | 109 | 225.85 | 24,617 |
| 2021-02-04 | Summy Amy B. (EVP, Chief Marketing Officer) | Option Ex | 266 | .00 | 0 |
| 2021-02-04 | Schroeder Mark S (EVP, President-Diagnostics Lab) | Option Ex | 560 | .00 | 0 |
| 2021-02-04 | Kirchgraber Paul R (CEO, Covance Drug Development) | Option Ex | 560 | .00 | 0 |
| 2021-02-04 | Seltz Judith C (EVP, CHRO) | Option Ex | 280 | .00 | 0 |
| 2021-02-04 | Caveney Brian J (EVP, President of Diagnostics) | Option Ex | 560 | .00 | 0 |
| 2021-02-04 | Davis Jeffrey A. (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Gilliland Dwight Gary (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Parham Richelle P (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Van Der Vaart Sandra D (EVP, Chief Legal Officer) | Option Ex | 300 | .00 | 0 |
| 2021-02-04 | Kong Garheng (Director) | Option Ex | 986 | .00 | 0 |
| 2021-02-04 | Wilkinson Peter J (SVP, Chief Accounting Officer) | Option Ex | 150 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
of LH listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Labcorp Holdings Inc. (symbol LH,
CIK number 920148) see
the Securities and Exchange Commission (SEC) website.